Hemorrhagic features and the application of recombinant activated factor VII in liver transplantation

Liu Jian-ping,Tao Chen,Jie Wang,Pang Wang,Peng Shu-ling,Jue Li,Ou Qing-jia

DOI: https://doi.org/10.3969/j.issn.1673-8225.2009.18.043

2009-01-01

Abstract:Background: Hemorrhage, hemostasis, and blood coagulation, as well as the application of hemostasis measures, in the liver transplantation have been poorly understood. There have been no protocols regarding routine hemostasis. Objective: To investigate the hemorrhagic features in each phase and to observe the application efficacy of recombinant activated factor V II (rFV II a) during the liver transplantation. Design, Time and Setting: A retrospective case analysis, controlled observation experiment was performed at the Department of Common Surgery, Second Affiliated Hospital of Sun Yat-sen University between April 2001 and July 2006. Participants: Fifteen patients who received liver transplantation between April 2001 and March 2003 served as retrospective study subjects. An additional 28 patients who underwent liver transplantation between March 2003 and July 2006 were randomly and evenly divided into two groups: rFV II a and control. Methods: The hemorrhage rule of 15 patients who received liver transplantation in the protophase was retrospectively analyzed and the hemorrhagic feature in each time period was localized. A comparative observation was performed in the 28 patients in the anaphase. The rFV II a group received an intravenous injection of 70-80 μ g/kg rFV II a for 3-5 minutes. Simultaneously, the control group was given 50 mL physiological saline in parallel. Main Outcome Measures: Hemorrhage volume of 15 patients that received liver transplantation in each phase; prothrombin time, activated partial thromboplastin time, and total hemorrhage volume prior to and 30 minutes after rFV II a application in 14 patients who received liver transplantation. Results: Extensive errhysis was a primary cause of hemorrhage in the liver transplantation. Hemorrhage primarily occurred in the phase of diseased liver resection (i.e., pre-anhepatic phase). rFV II a could well improve various coagulation functional indices, i.e., thromboelastography indices (reaction time, coagulation time, α angle, and maximum amplitude) and routine blood indices (prothrombin time and activated partial thromboplastin time). Compared with the control group, hemorrhage volume was obviously decreased and transplantation time was significantly shorter in the rFV II a group. In addition, no thrombotic complications were found in the rFV II a group during the observation period. Conclusion: The pre-anhepatic phase is a primary hemorrhage phase during the liver transplantation. rFV II a can be successfully applied for liver transplantation.